09:21 AM EST, 02/09/2026 (MT Newswires) -- (Updates with Hims & Hers response to a request for comment in the third paragraph.)

Novo Nordisk ( NVO ) said Monday it has filed a lawsuit against Hims & Hers (HIMS) for alleged patent infringement over the telehealth company's mass marketing of unapproved versions of Novo's semaglutide products, Wegovy and Ozempic.

"Hims & Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the [US Food and Drug Administration's] gold standard review process -- that's dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective," said John Kuckelman, Novo senior vice president, Group General Counsel, in a statement.

The lawsuit is a "blatant attack" on millions of US citizens relying on compounded drugs for access to personalized care, a Hims & Hers spokesperson told MT Newswires via email. "Once again, Big Pharma is weaponizing the US judicial system to limit consumer choice. This lawsuit attacks more than just one medication or company -- it directly assaults a well-established, vital component of US pharmacy practice that has improved patient care for everything from obesity to infertility to cancer," the spokesperson added.